Immune cells take aim at childhood cancers in new safety trial
NCT ID NCT07172958
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This early-phase study tests a combination of two types of immune cells (B7-H3 CAR T cells and PRAME-specific T cells) in children with relapsed or treatment-resistant cancers like rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, and Wilms tumor. The main goal is to check safety and find the best dose, not to cure the disease. Up to 18 participants will receive the cells after chemotherapy to see if the treatment is tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Childrens National Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.